Regenxbio RGNX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -292.3%-198pp | -94.6%+1.5pp | -96%+9.6pp | -105.7%-5.3pp | -100.4%+180pp | |
| Net margin | -330.2%-216pp | -113.8%-3.5pp | -110.3%+2.4pp | -112.7%-12.1pp | -100.6%+172pp | |
| EBITDA margin | -274.6%-189pp | -85.4%+0.8pp | -86.3%+9.2pp | -95.5%-5.3pp | -90.2%+170pp | |
| Free cash flow margin | -269.2%-195pp | -74.1%-8.3pp | -65.9%-7.7pp | -58.2%-2.7pp | -55.5%+155pp | |
| Returns | ||||||
| Return on equity | -196.4%-89.4pp | -107%-30.1pp | -76.9%-14.4pp | -62.5%-15.1pp | -47.4%+32.1pp | |
| Return on assets | -69.6%-27.5pp | -42.2%-8.1pp | -34.1%-3.5pp | -30.5%-2.4pp | -28.2%+15.5pp | |
| Return on invested capital | -170.6%-94.9pp | -75.7%-14.7pp | -61%-5.0pp | -56%-2.6pp | -53.4%+18.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×-0.2× | 0.4×+0.1× | 0.3×0.0× | 0.3×0.0× | 0.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.6×+0.2× | 2.4×-0.3× | 2.7×-0.5× | 3.1×+0.2× | 2.9×+0.2× | |
| Quick ratio | 2.6×+0.2× | 2.4×-0.3× | 2.7×-0.5× | 3.1×+0.2× | 2.9×+0.2× | |
| Cash ratio | 0.2×-0.1× | 0.3×-0.2× | 0.5×-0.2× | 0.7×-0.6× | 1.2×+0.7× | |
| Leverage | ||||||
| Debt-to-equity | 3.4×+2.7× | 0.7×+0.2× | 0.5×+0.1× | 0.4×+0.1× | 0.3×0.0× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | |
| Interest coverage | -5.7×-2.1× | -3.6×+0.1× | -3.7×+1.8× | -5.5×+2.6× | -8.2×+10.3× | |
| Per Share | ||||||
| Book value per share | $0.40-79.8% | $1.99-36.2% | $3.12-24.7% | $4.15-22.1% | $5.33+1.6% | |
| Valuation | ||||||
| Market capitalization | $529.38M+24.6% | $728.97M+49.5% | $487.46M+13.0% | $431.33M+20.4% | $358.12M-6.5% | |
| Enterprise value | $585.22M+56.3% | $768.01M+52.0% | $505.17M+17.6% | $429.47M+39.5% | $307.86M-24.4% | |
| Price / sales | 6×+3.3× | 4.3×+1.3× | 3×+0.3× | 2.8×+0.5× | 2.3×-2.3× | |
| Price / book | 25.1×+23.6× | 7.1×+4.1× | 3×+1.0× | 2×+0.7× | 1.3×-0.2× | |
| EV / sales | 6.7×+4.3× | 4.5×+1.4× | 3.1×+0.4× | 2.8×+0.8× | 2×-2.9× | |
| Free cash flow yield | -44.7%-24.2pp | -17.3%+4.5pp | -21.8%-0.8pp | -21%+3.2pp | -24.3%+21.6pp | |
| Earnings yield | -54.8%-17.7pp | -26.6%+9.9pp | -36.5%+4.2pp | -40.7%+3.3pp | -44%+15.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Regenxbio's profit margins?
- Regenxbio (RGNX) runs a 59.7% gross margin and a -292.3% operating margin, with a -330.2% net margin.
- Where do Regenxbio's ratios come from?
- Every ratio is computed from Regenxbio's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
